Literature DB >> 11867743

Invariant chain induces B cell maturation in a process that is independent of its chaperonic activity.

Didi Matza1, Frida Lantner, Yoel Bogoch, Liat Flaishon, Rami Hershkoviz, Idit Shachar.   

Abstract

Early stages of B cell development take place in the bone marrow, resulting in formation of immature B cells, which migrate to the spleen for their final differentiation into mature cells. This final maturation step is essential for B cells to become responsive to antigens and to participate in the immune response. Previously, we showed that the MHC class II chaperone, invariant chain (Ii), controls the differentiation of B cells from the immature to the mature stage. In this study, by generating transgenic mice expressing truncated Ii lacking its luminal domain, we could dissect the chaperonin activity of Ii from its role in B cell maturation. We demonstrate in vivo that Ii N-terminal domain is directly involved in the maturation of B cells and is sufficient to promote B cell differentiation.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11867743      PMCID: PMC122465          DOI: 10.1073/pnas.052703299

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  41 in total

1.  A role for the transmembrane domain in the trimerization of the MHC class II-associated invariant chain.

Authors:  J B Ashman; J Miller
Journal:  J Immunol       Date:  1999-09-01       Impact factor: 5.422

2.  B cell development in the spleen takes place in discrete steps and is determined by the quality of B cell receptor-derived signals.

Authors:  F Loder; B Mutschler; R J Ray; C J Paige; P Sideras; R Torres; M C Lamers; R Carsetti
Journal:  J Exp Med       Date:  1999-07-05       Impact factor: 14.307

3.  Requirement for invariant chain in B cell maturation and function.

Authors:  I Shachar; R A Flavell
Journal:  Science       Date:  1996-10-04       Impact factor: 47.728

4.  MHC class II expression in double mutant mice lacking invariant chain and DM functions.

Authors:  G Kenty; W D Martin; L Van Kaer; E K Bikoff
Journal:  J Immunol       Date:  1998-01-15       Impact factor: 5.422

5.  B lymphocyte development and activation independent of MHC class II expression.

Authors:  J S Markowitz; P R Rogers; M J Grusby; D C Parker; L H Glimcher
Journal:  J Immunol       Date:  1993-02-15       Impact factor: 5.422

Review 6.  Lymphocyte homing and homeostasis.

Authors:  E C Butcher; L J Picker
Journal:  Science       Date:  1996-04-05       Impact factor: 47.728

7.  BALB/c invariant chain mutant mice display relatively efficient maturation of CD4+ T cells in the periphery and secondary proliferative responses elicited upon peptide challenge.

Authors:  G Kenty; E K Bikoff
Journal:  J Immunol       Date:  1999-07-01       Impact factor: 5.422

8.  Mice lacking all conventional MHC class II genes.

Authors:  L Madsen; N Labrecque; J Engberg; A Dierich; A Svejgaard; C Benoist; D Mathis; L Fugger
Journal:  Proc Natl Acad Sci U S A       Date:  1999-08-31       Impact factor: 11.205

9.  Characterization of immature B cells by a novel monoclonal antibody, by turnover and by mitogen reactivity.

Authors:  A G Rolink; J Andersson; F Melchers
Journal:  Eur J Immunol       Date:  1998-11       Impact factor: 5.532

10.  B lymphocyte chemotaxis regulated in association with microanatomic localization, differentiation state, and B cell receptor engagement.

Authors:  C C Bleul; J L Schultze; T A Springer
Journal:  J Exp Med       Date:  1998-03-02       Impact factor: 14.307

View more
  28 in total

1.  The cytokine midkine and its receptor RPTPζ regulate B cell survival in a pathway induced by CD74.

Authors:  Sivan Cohen; Or-yam Shoshana; Einat Zelman-Toister; Nitsan Maharshak; Inbal Binsky-Ehrenreich; Maya Gordin; Inbal Hazan-Halevy; Yair Herishanu; Lev Shvidel; Michal Haran; Lin Leng; Richard Bucala; Sheila Harroch; Idit Shachar
Journal:  J Immunol       Date:  2011-12-02       Impact factor: 5.422

2.  The chondroitin sulfate form of invariant chain trimerizes with conventional invariant chain and these complexes are rapidly transported from the trans-Golgi network to the cell surface.

Authors:  Lynne S Arneson; Jim Miller
Journal:  Biochem J       Date:  2007-08-15       Impact factor: 3.857

3.  CD74 Deficiency Mitigates Systemic Lupus Erythematosus-like Autoimmunity and Pathological Findings in Mice.

Authors:  Yi Zhou; Huimei Chen; Li Liu; Xueqing Yu; Galina K Sukhova; Min Yang; Lijun Zhang; Vasileios C Kyttaris; George C Tsokos; Isaac E Stillman; Takaharu Ichimura; Joseph V Bonventre; Peter Libby; Guo-Ping Shi
Journal:  J Immunol       Date:  2017-02-20       Impact factor: 5.422

4.  A role for the B-cell CD74/macrophage migration inhibitory factor pathway in the immunomodulation of systemic lupus erythematosus by a therapeutic tolerogenic peptide.

Authors:  Smadar Lapter; Hava Ben-David; Amir Sharabi; Heidy Zinger; Alona Telerman; Maya Gordin; Lin Leng; Richard Bucala; Idit Shachar; Edna Mozes
Journal:  Immunology       Date:  2010-08-25       Impact factor: 7.397

5.  CD74 is a survival receptor on colon epithelial cells.

Authors:  Nitsan Maharshak; Sivan Cohen; Frida Lantner; Gili Hart; Lin Leng; Richard Bucala; Idit Shachar
Journal:  World J Gastroenterol       Date:  2010-07-14       Impact factor: 5.742

6.  Molecular cloning and expression of two chicken invariant chain isoforms produced by alternative splicing.

Authors:  Dalian Zhong; Weiyi Yu; Yuhua Liu; Jing Liu; Jinnian Li
Journal:  Immunogenetics       Date:  2004-11-16       Impact factor: 2.846

Review 7.  The biological function and significance of CD74 in immune diseases.

Authors:  Huiting Su; Ning Na; Xiaodong Zhang; Yong Zhao
Journal:  Inflamm Res       Date:  2016-10-17       Impact factor: 4.575

8.  A retroviral mutagenesis screen identifies Cd74 as a common insertion site in murine B-lymphomas and reveals the existence of a novel IFNgamma-inducible Cd74 isoform.

Authors:  Magdalena Pyrz; Bruce Wang; Matthias Wabl; Finn Skou Pedersen
Journal:  Mol Cancer       Date:  2010-04-23       Impact factor: 27.401

9.  Mad3 negatively regulates B cell differentiation in the spleen by inducing Id2 expression.

Authors:  Yael Gore; Frida Lantner; Gili Hart; Idit Shachar
Journal:  Mol Biol Cell       Date:  2010-04-07       Impact factor: 4.138

10.  Combining milatuzumab with bortezomib, doxorubicin, or dexamethasone improves responses in multiple myeloma cell lines.

Authors:  Rhona Stein; Mitchell R Smith; Susan Chen; Maria Zalath; David M Goldenberg
Journal:  Clin Cancer Res       Date:  2009-04-07       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.